Hinova Pharmaceuticals Receives FDA Fast Track Designation for HP518 for Treatment of AR+ Triple-Negative Breast Cancer

Hinova Pharmaceuticals, Inc. announced that the US FDA has granted Fast Track designation for HP518, an investigational drug for the treatment of androgen-receptor positive TNBC.